Cargando…
Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma
Grade-3 follicular lymphoma (FL) has aggressive clinical behavior. To evaluate the optimal first transplantation approach in relapsed/refractory grade-3 FL patients, we compared the long-term outcomes after allogeneic (allo-) vs. autologous hematopoietic cell transplantation (auto-HCT) in the rituxi...
Autores principales: | Klyuchnikov, Evgeny, Bacher, Ulrike, Ahn, Kwang Woo, Carreras, Jeanette, Kröger, Nicolaus M., Hari, Parameswaran N., Ku, Grace H., Ayala, Ernesto, Chen, Andy I., Chen, Yi-Bin, Cohen, Jonathon B., Freytes, César O., Gale, Robert Peter, Kamble, Rammurti T., Kharfan-Dabaja, Mohamed A., Lazarus, Hillard M., Martino, Rodrigo, Mussetti, Alberto, Savani, Bipin N., Schouten, Harry C., Usmani, Saad Z., Wiernik, Peter H., Wirk, Baldeep, Smith, Sonali M., Sureda, Anna, Hamadani, Mehdi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4703480/ https://www.ncbi.nlm.nih.gov/pubmed/26437062 http://dx.doi.org/10.1038/bmt.2015.223 |
Ejemplares similares
-
ALTERNATIVE DONORS EXTEND TRANSPLANTATION FOR PATIENTS WITH LYMPHOMA WHO LACK AN HLA MATCHED DONOR
por: Bachanova, Veronika, et al.
Publicado: (2014) -
Clinical, Diagnostic and Prognostic Characteristics of Primary Cutaneous Gamma Delta T-cell Lymphomas
por: Muhsen, Ibrahim N., et al.
Publicado: (2022) -
Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: A Center for International Blood and Marrow Transplant Research Analysis
por: Mahindra, Anuj, et al.
Publicado: (2017) -
Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia: No Impact of Pre-transplant Extramedullary Disease on Outcome
por: Goyal, Sagun D., et al.
Publicado: (2015) -
Early Relapse after Autologous Hematopoietic Cell Transplantation remains a Poor Prognostic Factor in Multiple Myeloma but Outcomes Have Improved Over Time
por: Kumar, Shaji K, et al.
Publicado: (2017)